Skip to content

News

Press Release: Cancer Advocates Debunk Huckabee’s Misleadin...

Press Release: Cancer Advocates Debunk Huckabee’s Misleading Comments on Oral Contraceptives

FOR IMMEDIATE RELEASE: January 24, 2014 Washington, DC—In response to a recent speech by Mike Huckabee, in which he stated that women use oral contraceptives because they “cannot control their libidos or their reproductive systems,” the Ovarian Cancer National Alliance issued the following statement from CEO Calaneet Balas: “In his quest for a quotable sound … Continued

OCRFA Research Identifies Biomarker that May Predict Treatment Response

OCRFA Research Identifies Biomarker that May Predict Treatment Response

(January 13, 2014) Researchers at Case Western Reserve University, led by OCRFA grantee Analisa DiFeo, PhD have identified a microRNA biomarker that shows promise in predicting treatment response in the most common form of ovarian cancer – a finding that has the potential to improve outcomes for patients with the disease.  The findings were published … Continued

Ovarian Cancer Research Fund Awards a Record-Breaking $6.9 ...

Ovarian Cancer Research Fund Awards a Record-Breaking $6.9 Million in Grants

Kicks off 20th Anniversary with an unprecedented grant award for scientific research and gynecologic cancer patient support program New York, NY January 13, 2014 — To mark its 20th anniversary, Ovarian Cancer Research Fund has awarded a record-breaking $6.9 million in scientific research grants for ovarian cancer and program grants to support gynecologic cancer patients. … Continued

Meet OCRF’s 2014 Grant Recipients

Meet OCRF’s 2014 Grant Recipients

OCRF has awarded $6.5 million in research grants to 22 scientists at leading medical institutions across the country.

OCRF Research Finds New “Chemoimmunotherapy” Ma...

OCRF Research Finds New “Chemoimmunotherapy” May Be New Treatment Option

New research funded by OCRF shows that treatment with the drug decitabine, prior to administration of chemotherapy and a cancer vaccine, yielded clinical benefit for women with recurrent ovarian cancer. This suggests that this combinatorial “chemoimmunotherapy” may provide a new treatment option for patients with this disease. Results of this phase I clinical trial, which … Continued

OCRF Research Sheds Light on Ovarian Cancer Origins in BRCA...

OCRF Research Sheds Light on Ovarian Cancer Origins in BRCA Mutation Carriers

A team of current and former OCRF grantees at Brigham and Women’s Hospital, Harvard Medical School and Dana-Farber Cancer Institute has developed genetically engineered mouse models of high-grade serous ovarian cancer that shed light on the pathogenesis of ovarian cancer for BRCA1/2 mutation carriers.  These models, which target the cell of origin (fallopian tube secretory cells) and recreate key genetic … Continued

OCRF Research Shows that Combining Targeted Agents is Effec...

OCRF Research Shows that Combining Targeted Agents is Effective Against Ovarian Cancer

New research funded in part by OCRF has shown that combining microRNA and siRNAs may be an effective new approach to developing better targeted therapies for ovarian cancer.  The research was reported in the November 2013 issue of Cancer Discovery, where the findings were also highlighted in an editorial commentary.  The research was funded in … Continued

Q&A with Maria Barbolina, Ph.D.

Q&A with Maria Barbolina, Ph.D.

Dr. Maria Barbolina is a 2013 Liz Tilberis Early Career Award grant recipient. In this interview with OCRF’s Sarah DeFeo, Dr. Barolina discusses her research and what it means to receive a grant from OCRF. Sarah DeFeo:  Tell us a little about yourself. Maria Barbolina:  I live in Chicago now, but my life started on the … Continued

OCRF Researchers Review Preclinical Models Used in Ovarian ...

OCRF Researchers Review Preclinical Models Used in Ovarian Cancer Research

In a review article published online in Oncogene on August 12, OCRF-funded researchers provide a comprehensive review of pre-clinical models used in ovarian cancer research.  The authors, including OCRF grantees Ernst Lengyel, Daniela Matei, Ken Nephew, and Joanna Burdette, explore current experimental models and reflect on the strengths and weaknesses for each method.  In addition, … Continued

Ovarian Cancer Research Fund and National Sponsor QVC Expan...

Ovarian Cancer Research Fund and National Sponsor QVC Expand Woman to Woman Program

Gynecologic Cancer Patients to Receive New Support in Tampa, Fla. and in Stanford, Calif. WEST CHESTER, Pa (Thursday, July 11, 2013) —Ovarian Cancer Research Fund (OCRF) and QVC today announced two new Woman to Woman grant recipients, Moffitt Cancer Center in Tampa, Fla. and Stanford Women’s Cancer Center in Stanford, Calif. QVC united with OCRF … Continued

After Angelina: What Do You Need to Know About Ovarian and ...

After Angelina: What Do You Need to Know About Ovarian and Breast Cancer Risk?

Experts agree: “If you or a close relative has been diagnosed with ovarian cancer, speak to your doctor about getting genetic counseling.” In the wake of Angelina Jolie’s announcement that she carries a genetic mutation linked to breast and ovarian cancers, thousands of women are wondering whether they are at risk. To address their concerns, … Continued

Stay Informed

Get email updates about research news, action alerts, and ways to join the fight.

We care about your data. Read our privacy policy.